Portmanteau inhibitor

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

A portmanteau inhibitor is a drug which is a combination of two drug molecules, each of which is itself a type of inhibitor. The term was coined in 2007 by University of Minnesota researchers who designed and synthesized a combination HIV Reverse transcriptase inhibitor and an Integrase inhibitor.^[1]^[2]^[3]

Footnotes

↑ "U of M researchers announce advance in treatment of HIV". 25 July 2007. Unknown parameter |accessed-date= ignored (help)
↑ "Researchers Discover New Method To Combat HIV". 25 July 2007. Unknown parameter |accessed-date= ignored (help)
↑ Zhengqiang Wang, Eric M. Bennett, Daniel J. Wilson, Christine Salomon, and Robert Vince (2007). "Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase". Journal of Medicinal Chemistry. 50 (15): 3416-3419. PMID 17608468.

Template:Pharmacology-stub

[KARE11_story-1] "U of M researchers announce advance in treatment of HIV". 25 July 2007. Unknown parameter |accessed-date= ignored (help)

[scidaily_story-2] "Researchers Discover New Method To Combat HIV". 25 July 2007. Unknown parameter |accessed-date= ignored (help)

[PMID_17608468-3] Zhengqiang Wang, Eric M. Bennett, Daniel J. Wilson, Christine Salomon, and Robert Vince (2007). "Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase". Journal of Medicinal Chemistry. 50 (15): 3416-3419. PMID 17608468.

[1]

[2]

[3]

v t e Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI)	Abacavir (ABC)° • Emtricitabine° • Lamivudine (3TC)° • Tenofovir° • Didanosine • Zidovudine (AZT) • Apricitabine^† • Stampidine^† • Elvucitabine^† • Racivir^† • Amdoxovir^† • Stavudine^‡ • Zalcitabine^‡
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)	Efavirenz° • Nevirapine • Etravirine • Rilpivirine^† • Loviride^‡ • Delavirdine^‡
Protease Inhibitors (PI)	Atazanavir° • Fosamprenavir° • Lopinavir° • Darunavir • Nelfinavir • Ritonavir • Saquinavir • Tipranavir • Amprenavir^‡ • Indinavir^‡
Entry/fusion inhibitors	Enfuvirtide • Maraviroc • Vicriviroc^† • PRO 140^† • Ibalizumab^†
Integrase inhibitors	Raltegravir • Elvitegravir^†
Maturation inhibitors	Bevirimat^† • Vivecon™^†
Combined formulations	Combivir • Atripla • Trizivir • Truvada • Kaletra • Epzicom
Other & experimental agents	Foscarnet • Hydroxyurea • Synergistic enhancers • Epigallocatechin gallate • Portmanteau inhibitors • Globoidnan A • Griffithsin • Diarylpyrimidines • Calanolide A • Cyanovirin-N • Miltefosine
°DHHS preferred first-line agent. ^†Undergoing clinical trials, not FDA approved. ^‡Formerly or rarely used agent.

Portmanteau inhibitor

Footnotes

Navigation menu